Correlation Engine 2.0
Clear Search sequence regions


Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Citation

John D Minna, Jonathan Dowell. Erlotinib hydrochloride. Nature reviews. Drug discovery. 2005 May;Suppl:S14-5

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 15962526

View Full Text